Ipamorelin: A Selective Ghrelin Receptor Agonist for Pulsatile Growth Hormone Release

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to ipamorelin. Ipamorelin is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Growth hormone secretagogues became widely discussed because they appeared to offer something exogenous HGH could not: pulsatile, physiologically regulated GH release without bypassing the hypothalamic feedback loop. Within that class, ipamorelin attracted particular scientific attention for a different reason. Unlike most of its predecessors, it appeared to stimulate GH selectively without triggering the broader hormonal cascade. That specific property, selectivity, became both ipamorelin's scientific claim to distinction and the feature most frequently misrepresented in non-clinical contexts.

This article explains what ipamorelin is, how it interacts with the ghrelin receptor, what the published research actually shows, and where the evidence ends.

Key Takeaways

• Regulatory Status: Not FDA-approved for human use. As of September 2023, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the FD&C Act, meaning it is prohibited from use in compounded medications for human administration. Ipamorelin has never received FDA approval for any indication.
• Research Stage: Preclinical data available; one failed Phase 2 RCT (postoperative ileus, 2014). No completed human efficacy trials for GH-related indications.
• Availability: Not legally marketed for human use in the United States. Superpower Health does not offer this substance.
• Prescribing information: View compound reference data (PubChem CID 20515892)
• What it is: A synthetic pentapeptide that selectively activates the growth hormone secretagogue receptor (GHS-R1a) to stimulate pulsatile GH release.
• What the evidence actually shows: Selective GH stimulation without cortisol or prolactin elevation in animal models; its sole human RCT failed to meet its primary endpoint.

Where Ipamorelin Comes From and How It Works

Origin and discovery

Ipamorelin (also referred to by its Novo Nordisk research designation NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s. It emerged from a medicinal chemistry program aimed at identifying orally active or injectable growth hormone secretagogues with an improved selectivity profile compared to earlier compounds in the class. Raun, Hansen, and colleagues, publishing in the European Journal of Endocrinology in 1998, first described ipamorelin as "the first selective growth hormone secretagogue" — a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that released GH in conscious swine with an ED50 of 2.3 ± 0.03 nmol/kg and an Emax of 65 ± 0.2 ng/mL plasma, at potency comparable to GHRP-6 but without the ACTH, cortisol, FSH, LH, prolactin, or TSH elevations seen with earlier GHRPs even at doses 200-fold above the GH-release ED50. The companion medicinal chemistry paper by Ankersen and colleagues in the Journal of Medicinal Chemistry that year detailed the SAR program and the new series of highly potent GH-releasing peptides derived from the ipamorelin scaffold. A 1999 paper by Hansen and colleagues in the European Journal of Endocrinology later characterized NN703, a subsequent orally active GH secretagogue from the same Novo Nordisk program. The compound does not occur naturally in the body; it is an entirely synthetic molecule.

The ghrelin receptor and GHS-R1a agonism

Ipamorelin works by binding to and activating the growth hormone secretagogue receptor subtype 1a, designated GHS-R1a. This receptor is the same receptor that ghrelin, the endogenous hunger and GH-releasing hormone, activates. In 1999, Kojima and colleagues identified ghrelin in a landmark paper in Nature, establishing it as the endogenous ligand for GHS-R1a. A 2005 review by Kojima and Kangawa in Physiological Reviews, a 2015 review by Müller and colleagues in Molecular Metabolism, and a 2020 review by Abizaid and Hougland in Trends in Endocrinology and Metabolism together provide comprehensive coverage of ghrelin receptor biology and its signaling complexity. An earlier 1998 review by Bowers in Cellular and Molecular Life Sciences remains an authoritative reference for the GHS class as a whole. Ipamorelin mimics this interaction: by binding GHS-R1a on somatotroph cells in the anterior pituitary, it triggers the release of growth hormone in a pulsatile pattern that preserves the hypothalamic feedback mechanisms governing GH secretion. This is mechanistically distinct from GHRH analogs such as sermorelin, which activate a separate receptor on the same cells. The two receptor pathways are complementary, which is why ipamorelin is sometimes studied alongside GHRH analogs; the combination article addresses that context separately.

The selectivity story: what makes ipamorelin different

Most growth hormone secretagogues developed before ipamorelin stimulated GH but also produced secondary hormonal effects. Arvat, di Vito, and colleagues in a 1997 study in Peptides, administered GHRP-2 and hexarelin (1 µg/kg IV) to young healthy adults and showed that both peptides produced GH responses greater than GHRH along with slight but real stimulation of prolactin, ACTH, and cortisol — with ACTH/cortisol-releasing activity similar in magnitude to that of human CRH — establishing that earlier-generation GHRPs are not hormonally "clean." The mechanism involves off-target activation of non-GHS-R1a pathways, including CRF (corticotropin-releasing factor) pathways. Ipamorelin's published pharmacological profile is substantially different. Raun and colleagues demonstrated in 1998 that equimolar doses of ipamorelin stimulated GH release in pigs at levels comparable to GHRP-6 while producing no statistically significant elevation in ACTH or cortisol. Prolactin was similarly unaffected. This three-way selectivity, GH stimulation without cortisol, prolactin, or ACTH elevation, established ipamorelin as the benchmark for GHS selectivity in the academic literature and drove its adoption in compounded practice before regulatory classification changed.

Pharmacokinetics: half-life and the pulsatility question

Ipamorelin is a peptide and is therefore rapidly cleared from circulation. Gobburu and colleagues in a 1999 PK/PD modeling study in Pharmaceutical Research, characterized ipamorelin behavior in human volunteers and reported a short half-life of approximately two hours. This rapid clearance is relevant to how the compound was used in compounded practice, typically via subcutaneous injection timed to align with the natural nocturnal GH pulse, but it also means the window of receptor activation is brief. The pulsatile GH release pattern generated by GHS-R1a agonism more closely resembles physiological secretion than continuous delivery of exogenous HGH, which suppresses endogenous pituitary output entirely. Malmlöf and colleagues in a 1999 paper in Growth Hormone and IGF Research, also demonstrated in rats that methylprednisolone (5.0 mg/kg for 8 days) did not blunt the acute plasma GH response to either ipamorelin or GHRH, and that repeated IV ipamorelin dosing (0.4 or 1.6 mg/kg/day × 10 days) in glucocorticoid-treated rats raised IGF-1 and significantly reduced methylprednisolone-induced weight loss (P < 0.05) — supporting that the GH-IGF-1 axis remains responsive to GHS stimulation during glucocorticoid exposure.

What the Human Evidence Looks Like

The only completed human RCT

As of April 2026, one completed, peer-reviewed randomized controlled trial of ipamorelin in humans has been published. Beck, Sweeney, and McCarter, publishing in the International Journal of Colorectal Disease in 2014, conducted a proof-of-concept Phase 2 RCT of ipamorelin for postoperative ileus following bowel resection. The trial was not an investigation of ipamorelin's growth-hormone-related effects; it tested whether the compound's gastroprokinetic properties could accelerate gastrointestinal recovery after bowel surgery. The study enrolled 117 patients (114 composed the safety and modified intent-to-treat populations) and randomized them to IV ipamorelin 0.03 mg/kg twice daily versus placebo for up to 7 days or hospital discharge, with median time to first tolerated meal as a key efficacy measure. The ipamorelin arm showed a numerical but non-significant improvement (25.3 vs. 32.6 hours, p = 0.15), no significant differences were seen on the key and secondary efficacy analyses, and the regimen was well tolerated. Ipamorelin did not meet its efficacy endpoints, and clinical development in this indication was discontinued. Preclinical gastrointestinal motility data from Venkova and colleagues in the Journal of Pharmacology and Experimental Therapeutics in 2009 and Greenwood-Van Meerveld and colleagues in the Journal of Experimental Pharmacology in 2012 had supported the rodent hypothesis; the human data did not replicate it.

GH-related effects: animal data and the evidence gap

The GH-releasing properties of ipamorelin, which drove its widespread use in compounded practice, have been studied in animals but not in completed human efficacy trials. Johansen and colleagues, publishing in Growth Hormone and IGF Research in 1999, demonstrated that ipamorelin induced statistically significant longitudinal bone growth in hypophysectomized rats. Svensson and colleagues published a 2000 study in the Journal of Endocrinology showing that ipamorelin and GHRP-6 both increased bone mineral content in adult female rats. Lall and colleagues reported in 2001 in Biochemical and Biophysical Research Communications that GH secretagogues, including ipamorelin, stimulated adiposity-related changes in rodents through a GH-independent pathway. Jiménez-Reina, Cañete, and colleagues, in a 2002 study in Histology and Histopathology, treated young female rats with ipamorelin, GHRH, or saline for 21 days and reported that chronic ipamorelin exposure did not alter somatotroph ultrastructure but increased the volume density of secretion granules, consistent with sustained pituitary secretory activity without evident somatotroph exhaustion in this rodent model. All of these endpoints are preclinical. There are no completed human trials examining ipamorelin's effects on body composition, lean mass, bone density, recovery, or IGF-1 in humans for these indications.

Why ipamorelin became the dominant GHS in compounded practice

Despite the absence of human efficacy data for GH-related endpoints, ipamorelin became the most commonly prescribed growth hormone secretagogue in US compounding practice in the years before the 2023 FDA action. Two factors drove this. First, its selectivity profile, established in the 1998 Raun paper, was accurately communicated in clinical circles as a meaningful pharmacological advantage over GHRP-2, GHRP-6, and hexarelin. Second, the IGF-1 monitoring data available from the literature, including a 2017 retrospective study by Sigalos, Pastuszak, and colleagues in the American Journal of Men's Health — 14 men on testosterone therapy treated with a GHRP-6 / GHRP-2 / SERM stack, with mean IGF-1 rising from 159.5 to 239.0 ng/mL (p < 0.0001) — provided a measurable biomarker endpoint that providers could track, although the small retrospective design limits the strength of inference. That combination, a clean selectivity story and a trackable biomarker, created a compelling clinical rationale even in the absence of Phase 3 efficacy data. The 2023 FDA Category 2 classification ended legal access through compounding.

Regulatory and Legal Status

FDA classification

As of April 2026, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the Federal Food, Drug, and Cosmetic Act. This classification, which the FDA finalized in September 2023, places ipamorelin on the list of substances that may not be used in compounded drug preparations for human administration under the 503A compounding framework. Category 2 does not mean the substance is inherently dangerous; it means the FDA determined the substance lacks sufficient evidence to support a finding that the benefit-risk profile justifies inclusion on the list of bulk substances that may be compounded. Ipamorelin has never received FDA approval as a drug for any human therapeutic indication. The reference source for the 503A bulk drug substances process is the FDA's current 503A bulk drug substances list.

Sport ban status

For athletes, there is a separate regulatory consideration. As of the 2026 WADA Prohibited List, ipamorelin is prohibited under category S2 (peptide hormones, growth factors, related substances, and mimetics). This classification applies both in- and out-of-competition. Detection methodology for ipamorelin metabolites in urine following nasal or injectable administration was characterized by Semenistaya, Zvereva, and colleagues in a 2015 study in Drug Testing and Analysis, meaning ipamorelin is detectable through established anti-doping testing. A 2012 review by Baumann in Endocrine Reviews provides authoritative context on GH doping detection strategies across this class. Competitive athletes subject to WADA or USADA jurisdiction who use ipamorelin risk disqualification.

What this means practically

With that regulatory context established, ipamorelin is not legally obtainable in pharmaceutical-grade form for human use in the United States. Products labeled as ipamorelin sold through online vendors, research chemical suppliers, or gray-market peptide sources are not FDA-regulated. They are manufactured without pharmaceutical oversight and have not been tested for purity, sterility, or accurate dosing. Independent testing of peptide research products has repeatedly found contamination, incorrect concentrations, and misidentified compounds. There is no legal compounding pathway for ipamorelin under current 503A rules, and Superpower does not offer ipamorelin in any form.

Ipamorelin vs. Related Growth Hormone Secretagogues: Key Differences

Ipamorelin belongs to the GHS-R1a agonist class, which it shares with GHRP-2, GHRP-6, and hexarelin. It also operates in the same physiological context as GHRH analogs such as sermorelin and tesamorelin, though through an entirely different receptor pathway. Understanding these distinctions requires attention to both receptor biology and the evidence base for each compound.

The pharmacological distinction between ipamorelin and GHRP-2, GHRP-6, and hexarelin centers on selectivity. All four compounds activate GHS-R1a and stimulate GH release. GHRP-2 and hexarelin, however, also activate non-GHS-R1a pathways that drive ACTH and cortisol secretion. The 1997 Arvat paper establishing this in humans remains the primary reference. Ipamorelin does not produce these secondary hormonal effects at equivalent doses, according to the 1998 Raun selectivity data. This selectivity profile was the scientific basis for preferring ipamorelin in clinical practice, and it distinguishes ipamorelin from hexarelin, which also carries evidence of cardiac effects not seen with ipamorelin. It should be noted that GHRP-2, GHRP-6, and hexarelin are themselves not available through legal compounding channels and are not eligible for content on this platform.

The distinction between ipamorelin and GHRH analogs such as sermorelin involves a different comparison. Sermorelin activates the GHRH receptor on pituitary somatotrophs; ipamorelin activates GHS-R1a. These receptors are different proteins that initiate overlapping but distinct intracellular signaling cascades. Both ultimately result in GH release, but the regulatory inputs differ. Sermorelin's mechanism is subject to negative feedback via somatostatin; GHS-R1a agonism has a partially somatostatin-independent mechanism, which is why the two receptor pathways have been described as complementary in the preclinical literature. This comparison is provided for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases, and the comparison does not constitute a clinical recommendation.

Safety: What Is and Is Not Known

Absence of clinical safety data for GH-related uses

The only published human safety data for ipamorelin comes from the 2014 Beck postoperative ileus RCT and the 1999 Gobburu pharmacokinetic study in volunteers. Neither evaluated the safety profile associated with long-term subcutaneous administration for GH-related purposes. There are no Phase 1 or Phase 2 safety studies of ipamorelin for body composition, bone density, or recovery endpoints in humans. The absence of this data means that claims about ipamorelin's safety profile in the context of long-term use are not supported by clinical evidence. The 2018 class review by Sigalos and Pastuszak in Sexual Medicine Reviews characterized the available safety evidence for GH secretagogues as limited and noted that most data derive from short-duration studies. A more recent 2023 review by Smith and Thorner in the Journals of Gerontology Series A revisited the rationale for GHSs as potential therapeutics to restore GH secretion in older adults to young-adult levels, and a 2020 review by Sinha and colleagues in Translational Andrology and Urology addressed GHS use in body composition management in hypogonadal males — while cataloguing the evidence gap.

Risks from unregulated sources

Because ipamorelin has no legal compounding pathway in the United States, any product currently available for purchase is sourced from unregulated suppliers. Peptide products sold as research chemicals or through online vendors are not subject to FDA manufacturing standards. Contamination with endotoxins, incorrect peptide sequences, degraded material, and unknown impurities have been documented in independent analyses of gray-market peptide products. The Baumann 2012 Endocrine Reviews paper on GH doping in sport noted the quality control challenges specific to this category. Dosing inconsistency is a practical safety concern even in the absence of an inherent toxicological hazard from the compound itself.

Who Should Not Use Ipamorelin

Based on ipamorelin's proposed mechanisms and the evidence base for the GHS-R1a agonist class, the following groups face elevated theoretical risk. This is not an exhaustive safety profile, as comprehensive clinical safety data does not exist.

• Individuals with active or suspected malignancy: GH and IGF-1 stimulation are growth-promoting signals. The theoretical concern that GHS-R1a agonism could support tumor cell proliferation or angiogenesis is unresolved. No human safety data addresses this risk specifically for ipamorelin.
• Individuals with acromegaly or elevated baseline IGF-1: Ipamorelin stimulates GH release. In individuals already producing excess GH or IGF-1, additional receptor-mediated stimulation could compound existing risks.
• Individuals with type 2 diabetes or impaired glucose tolerance: GH has insulin-antagonist effects. Growth hormone secretagogues, including ipamorelin, carry a theoretical risk of worsening insulin resistance, a concern supported by preclinical adiposity data from Lall and colleagues.
• Competitive athletes subject to anti-doping rules: Ipamorelin is prohibited under the 2026 WADA Prohibited List (S2 category). Use carries the risk of a doping violation and associated sanctions.
• Pregnant or breastfeeding individuals: No safety data exists for these populations. GH axis manipulation during pregnancy or lactation is not supported by any published clinical evidence.
• Individuals with hypothyroidism or other pituitary axis disorders: GH secretagogue responses may be attenuated or unpredictable in the presence of thyroid or pituitary dysfunction. No clinical data characterizes ipamorelin's behavior in these populations.

Which Biomarkers Are Relevant if You Are Exploring Growth Hormone Science?

Understanding your baseline GH axis and metabolic markers provides meaningful context regardless of which interventions you are evaluating. These markers directly reflect the physiological pathways ipamorelin engages.

• IGF-1 (insulin-like growth factor 1): The primary downstream biomarker for GH axis activity. GH stimulates IGF-1 production primarily in the liver; circulating IGF-1 reflects integrated GH secretion over the preceding hours. Because GH itself has a short half-life and is released in pulses, IGF-1 is the practical clinical surrogate for GH axis function and the most relevant monitoring marker for any GHS intervention. The 2017 Sigalos and colleagues study specifically used serum IGF-1 as the primary efficacy biomarker in their GHS assessment. Understanding your baseline IGF-1 also matters in the context of the relationship between IGF-1 and longevity, where both deficiency and excess carry distinct risk profiles.
• Fasting glucose and insulin: GH has counter-regulatory effects on insulin, and GH secretagogue use carries a theoretical risk of impairing glucose homeostasis. Baseline fasting glucose and insulin quantify metabolic starting point and help identify individuals in whom GH axis stimulation would require closer monitoring.
• Cortisol: Ipamorelin's selectivity claim specifically concerns its lack of cortisol elevation versus GHRP-2, GHRP-6, and hexarelin. Measuring baseline cortisol provides a reference point relevant to understanding the compound's purported selectivity advantage and whether other variables (sleep, stress, hypothalamic function) are affecting the HPA axis independently.
• Comprehensive metabolic panel: Liver and kidney function testing establishes organ health baseline. The liver is the primary site of IGF-1 synthesis. Abnormal hepatic function can distort IGF-1 levels and confound interpretation of any GH axis intervention.
• Complete blood count: A general safety baseline. While ipamorelin does not have a known direct hematological effect, comprehensive baseline testing before evaluating any investigational compound is standard clinical practice.
• Body composition markers (where available): Because GH axis stimulation is studied for effects on lean mass and adipose tissue, having a quantified baseline for body composition biomarkers makes any changes in that domain interpretable over time.

When to Take This Seriously

If the symptoms that drive interest in growth hormone secretagogues, fatigue, poor recovery, changes in body composition, or disrupted sleep, are persistent and affecting quality of life, those are real concerns with established clinical pathways. A primary care physician, endocrinologist, or sports medicine provider can assess GH axis function through established diagnostic protocols. Understanding baseline IGF-1, glucose metabolism, thyroid function, and metabolic health through bloodwork provides the objective data that makes any clinical conversation productive. Starting with clear biomarker data gives any subsequent evaluation something concrete to work from.

That principle, test first so that decisions are grounded in data rather than symptoms alone, reflects Superpower's approach to preventive health: the conviction that understanding your biology is a precondition for every meaningful health decision, whether that involves established therapies or navigating emerging research.

IMPORTANT SAFETY INFORMATION

Ipamorelin is not FDA-approved for any indication and has never completed the Phase 3 clinical trials required for FDA drug approval. As of September 2023, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the FD&C Act, prohibiting its use in compounded medications for human administration. Superpower Health does not prescribe, sell, compound, or facilitate access to ipamorelin in any form.

There are no FDA-approved prescribing guidelines or established safety parameters for ipamorelin use in humans for growth hormone-related indications. The absence of completed Phase 1 safety trials for these indications means the human side effect profile, contraindication profile, and drug interaction profile are not established by clinical data.

Theoretical contraindications based on proposed mechanism: active or suspected malignancy (GH and IGF-1 stimulation may support tumor growth); acromegaly or elevated baseline IGF-1; type 2 diabetes or impaired glucose tolerance (GH has insulin-antagonist effects); pregnancy and breastfeeding (no safety data); known hypopituitary disorders requiring supervised GH management.

Warnings: Products sold online as ipamorelin are not FDA-regulated, lack pharmaceutical-grade purity standards, and may contain contaminants, incorrect concentrations, or misidentified compounds. Competitive athletes: ipamorelin is prohibited under the 2026 WADA Prohibited List (S2 category) both in- and out-of-competition. Long-term safety data in humans does not exist for GH-secretagogue indications.

As of April 2026, no compounding pharmacy may legally prepare ipamorelin for human use under Section 503A. Any ipamorelin product available for purchase in the United States falls outside the regulated pharmaceutical supply chain.

Additional Questions

What is the difference between ipamorelin and GHRP-2 or GHRP-6?

The primary distinction is hormonal selectivity. Ipamorelin, as Raun and colleagues established in 1998, stimulates GH without producing significant elevations in ACTH, cortisol, or prolactin. GHRP-2 and hexarelin activate non-GHS-R1a pathways that elevate cortisol and ACTH alongside GH release, as documented by Arvat and colleagues in 1997. GHRP-6 also lacks ipamorelin's selectivity, with additional effects on appetite mediated by ghrelin pathway activation. GHRP-2, GHRP-6, and hexarelin are themselves Category 2 or otherwise ineligible for compounding and are not offered by Superpower.

What biomarker should I monitor if I am interested in GH axis function?

IGF-1 is the primary clinical surrogate for integrated GH secretion. Because GH is released in short pulses and has a half-life of minutes, a single GH measurement is rarely clinically useful outside a provocation test. IGF-1, produced primarily in the liver in response to GH signaling, reflects cumulative GH output and is the standard monitoring biomarker used in GH-related research, including in the Sigalos and colleagues 2017 study of GHS effects on serum IGF-1 in hypogonadal men. Fasting glucose and a metabolic panel provide additional context for interpreting GH axis status and its relationship to insulin sensitivity.

Is ipamorelin prohibited in sport?

Yes. As of the 2026 WADA Prohibited List, ipamorelin is prohibited under category S2 (peptide hormones, growth factors, related substances, and mimetics), both in- and out-of-competition. Detection methodology in urine has been validated. Athletes subject to WADA or USADA jurisdiction who use ipamorelin risk anti-doping rule violations.